IL4 and asthma: In this sense, the role of dupilumab, a monoclonal antibody blocking IL-4 and IL-13 signaling pathway by inhibiting IL-4R alpha, is promising for the management of patients with asthma with reduced response to corticosteroids, as reviewed recently (28).